Peer-Reviewed Work

The research record behind the platform.

68 publications and conference contributions, a U.S. patent-pending application on the AEcelerate architecture; and the clinical work behind them, by our leadership and medical advisors; spanning AI benchmarking, clinical data science, hematology-oncology, and rheumatology.

AI & Clinical Data Science

Selected work on AI capability and clinical models.

From an expert-level AI benchmark in Nature to explainable machine-learning models of leukemia progression; the AI publications behind the platform's intelligence.

  1. 2026A benchmark of expert-level academic questions to assess AI capabilitiesAli DasouqiNature
  2. 2025Predicting the Regulatory Dynamics of AML Disease Progression from Longitudinal Multi-Modal Clinical DataMoaath Mustafa AliJ Med Syst
  3. 2025Navigating the Real World: The Limitations of AI in Spatial IntelligenceAli DasouqiJohns Hopkins University
  4. 2025Discovery of Dynamic Models for AML Disease Progression from Longitudinal Multi-Modal Clinical Data Using Explainable Machine LearningMoaath Mustafa AlimedRxiv
  5. 2024Humanity’s Last ExamAli DasouqiCenter for AI Safety
  6. 2023Demonstration of Advanced Predictive Analytics Using the COLM Quick Guides at Duke EnergyAli DasouqiElectric Power Research Institute
Portrait of Ali Dasouqi, PhD, MBA
AI Systems & Clinical Data Science

Ali Dasouqi, PhD, MBA

CEO & Founder at AEcelerate

A systems engineer and AI strategist, Ali led the U.S. patent-pending application on AEcelerate’s autonomous evidence architecture and publishes on the frontiers of AI capability; an expert-level AI benchmark in Nature, spatial-intelligence limits with Johns Hopkins, Humanity’s Last Exam with the Center for AI Safety, and applied predictive analytics with EPRI. He earned his PhD in mechanical engineering at the University of South Florida, where his fluid-dynamics research appeared in Experiments in Fluids and Physical Review Fluids; the same applied-modeling rigor he now directs at clinical data.

14Publications, patent, talks & media
2018 – 2026Publication years
Google Scholar profile
  1. 2026
  2. 2026
  3. 2025
  4. 2024
    Humanity’s Last Exam
    BenchmarkAli Dasouqi, et al.Center for AI Safety
  5. 2023
  6. 2022
    The effect of liquid properties on the release of gas from bursting bubbles
    Journal ArticleA. A. Dasouqi, J. Ghossein, D. W. MurphyExperiments in FluidsCited by 10
  7. 2021
    Bursting bubbles and the formation of gas jets and vortex rings
    Journal ArticleA. A. Dasouqi, G. S. Yeom, D. W. MurphyExperiments in FluidsCited by 22
  8. 2021
  9. 2020
    Gas escape behavior from bursting bubbles
    Journal ArticleA. A. Dasouqi, D. W. MurphyPhysical Review FluidsCited by 5
  10. 2020
    Pterobots: Sea Butterflies as Soft Robot Models
    Conference AbstractA. Al Dasouqi, et al.University of California, San Diego
Show all 14 publications4 more · 2018–2019
  1. 2019
    Bursting bubbles blow smoke rings
    Media CoverageAli Dasouqi (featured research)Science
  2. 2019
    A Novel Cylindrical Clap-and-Fling Maneuver by Swimming Marine Snails
    Conference AbstractF. Karakas, A. Al Dasouqi, A. Maas, et al.APS Division of Fluid Dynamics Meeting
  3. 2018
    Time-Resolved Micro PIV Measurements around a Freely Flying Tiny Insect
    Conference AbstractD. Murphy, F. Karakas, A. Al Dasouqi, K. Garayev, et al.APS Division of Fluid Dynamics Meeting
  4. 2018
    Fluid mechanics of gas jets and vortex rings released from bursting bubbles
    Conference AbstractA. Al Dasouqi, D. MurphyBulletin of the American Physical SocietyCited by 1
Portrait of Dr. Moaath Mustafa Ali, MD, MPH
Hematology & Oncology

Dr. Moaath Mustafa Ali, MD, MPH

Clinical AI Advisor at AEcelerate

A hematologist and leukemia specialist at Cleveland Clinic and Assistant Professor of Medicine at Case Western Reserve University, Moaath works where clinical medicine meets machine learning; his data-science publications include explainable-ML models of AML disease progression from longitudinal multimodal clinical data (J Med Syst; medRxiv), alongside NCCN guideline contributions and first-authored real-world outcome studies across acute myeloid leukemia, lymphoma, and CAR-T cell therapy.

51PubMed-indexed publications
2014 – 2026Publication years
PubMed author record
  1. 2026
    Reply to "Does disease ontogeny matter more than JAK2 mutation status in acute myeloid leukemia?"
    CommentAlbliwi M, Nurse DP, Zabor EC, Hanna J, El-Asmar J, Bawwab A, Abuamsha H, Abu-Farsakh Y, Batah H, Rauf A, Nakitandwe J, Bosler DS, Parthasarathy PB, Alban T, Jain AG, Molina JC, Balderman S, Singh A, Gerds AT, Mukherjee S, Advani AS, Carraway HE, Mustafa Ali MKCancerPMID 42663330
  2. 2026
    Descriptive analysis of the causes and outcomes of patients admitted to intensive care unit in Gaza during June 2024: A prospective cohort study
    Abed A, Sammour AA, Aljerjawi S, Musallam R, Shaheen M, Sammour H, Alzghoul BN, Mustafa Ali MK, Naser AYMedicine (Baltimore)PMID 42536553
  3. 2026
    Longitudinal analysis of tyrosine kinase inhibitor therapy outcomes and BCR-ABL1 transcript decline velocity in chronic myeloid leukemia: A 16-year real-world study
    Mustafa Ali MK, Zabor EC, Abdurakhmanov K, Zureigat H, Mohamed AN, Alchirazi MA, Dhakal A, Mushtaq A, Rehman N, Bawwab A, Berube B, Khatib L, Jain AG, Molina JC, Balderman S, Singh A, Gerds AT, Sobecks R, Advani AS, Carraway HE, Kalaycio M, Mukherjee SCancerPMID 42455913
  4. 2026
    NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026
    GuidelinePollyea DA, Altman JK, Assi R, Bachiashvili K, Bhatt VR, Fathi AT, Fedorov K, Foran JM, Gojo I, Goldberg A, Hall AC, Jonas BA, Levine MR, Mangan J, Mannis G, Marcucci G, Mims A, Moriarty K, Mustafa Ali M, Neff J, Nejati R, Olin R, Patel A, Percival ME, Perl A, Pettit K, Rao D, Ravandi F, Schwabkey Z, Shallis R, Stahl M, Stone RM, Thota S, Uy GL, Walker A, Wang E, Awotiwon A, Roth SL, Stehman KJ Natl Compr Canc NetwPMID 42297017
  5. 2026
    Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors
    Chatterjee A, Mustafa Ali MK, Bailey CM, Liu Y, Small D, Smith CC, Traer E, Wang Y, Silvestri G, Baer MRLeukemiaPMID 42230959
  6. 2026
    Cytokine receptor and JAK/STAT pathway mutations in acute myeloid leukemia: Prevalence and clinical impact
    Albliwi M, Nurse DP, Zabor EC, Hanna J, El-Asmar J, Bawwab A, Abuamsha H, Abu-Farsakh Y, Batah H, Rauf A, Nakitandwe J, Bosler DS, Parthasarathy PB, Alban T, Jain AG, Molina JC, Balderman S, Singh A, Gerds AT, Mukherjee S, Advani AS, Carraway HE, Mustafa Ali MKCancerPMID 42175603
  7. 2026
    Real-World Survival Outcomes and Prognostic Factors in De Novo Stage IV Urothelial Bladder Cancer: A 13-Year Retrospective Cohort Study
    Mushtaq A, Zabor EC, Adcock B, Dhakal A, Rehman N, Alsabbagh Alchirazi M, Albliwi M, Zureigat H, Lee M, Hassan ANM, Batah H, Patel P, Patel M, Haddad SF, Vincek N, Mustafa Ali MKClin Genitourin CancerPMID 41934031
  8. 2026
    Cardiac safety profiles of first-generation vs second-generation BTK inhibitors: a meta-analysis
    Mushtaq A, Ahmed EN, Aljumaa R, E'mar AR, Badwan O, Ashruf O, Elshaer A, Shaik A, Baroudi M, Moudgil R, Mustafa Ali MKOncologistPMID 41871445
  9. 2026
    The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation
    Adcock B, Mustafa Ali MK, Zabor EC, Zureigat H, Batah H, Dhakal A, Lee M, Patel P, Patel M, Abu-Shawer O, Hassan A, Tomer J, Ingraham A, Makarov V, Ni Y, Alban T, Robertson S, Ma WW, Adjei AA, Chan TClin Cancer ResPMID 41642707
  10. 2026
    Comparative Outcomes of Intensive Chemotherapy Versus Venetoclax Plus Hypomethylating Agents in Acute Myeloid Leukemia Patients Aged 60-75 Years: A Propensity Score-Adjusted Cohort Study
    Albliwi M, Zabor EC, Hanna J, El-Asmar J, Nurse DP, Bawwab A, Abuamsha H, Abu-Farsakh Y, Rauf A, Batah H, Mohamed A, Alchirazi MA, Jain AG, Molina JC, Balderman S, Singh A, Gerds AT, Mukherjee S, Sobecks RM, Hamilton B, Advani AS, Carraway HE, Mustafa Ali MKClin Lymphoma Myeloma LeukPMID 40947327
Show all 51 publications41 more · 2014–2025
  1. 2025
  2. 2025
    Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors
    PreprintChatterjee A, Mustafa Ali MK, Bailey CM, Liu Y, Small D, Smith CC, Traer E, Wang Y, Silvestri G, Baer MRbioRxivPMID 41341164
  3. 2025
    Long-term outcomes of Extensive-Stage small cell lung cancer treated with chemotherapy or Chemo-immunotherapy: A propensity score adjusted cohort study
    Batah H, Zabor EC, Adcock B, Lee M, Patel P, Patel M, Zureigat H, Mohamed AN, Nurse DP, Bedelu YB, Tomer J, Delasos L, Hassan KA, Pennell NA, Shapiro MA, Stevenson J, Adjei AA, Mustafa Ali MKLung CancerPMID 41265379
  4. 2025
    Disparities in real-world treatment patterns of hypomethylating agents among patients with MDS in the United States
    Mukherjee S, Dong W, Gerds AT, Carraway HE, Singh A, Advani AS, Mustafa Ali MK, Molina JC, Balderman S, Jain A, Caimi P, Anwer F, Sekeres MA, Koroukian SMBlood NeoplasiaPMID 41146970
  5. 2025
    Prevalence of stress, anxiety and depression among healthcare workers in the Gaza strip
    Naser AY, Mustafa Ali M, Sammour AAH, Skaik AN, Abed A, Musallam R, Alsarafandi M, Halimy MI, Aljerjawi S, Habboub AE, Rassoul MA, Ghali A, Loubani M, Ramleth RK, Irfan B, Silevany F, Hamarshi MS, Abukhalaf AHI, Alzghoul BNMedicine (Baltimore)PMID 40922370
  6. 2025
    Impact of Cytogenetic Response to Therapy on Long-Term Survival in Acute Myeloid Leukemia
    Hanna J, Zabor EC, Albliwi M, El-Asmar J, Nurse DP, Bawwab A, Abuamsha H, Abu-Farsakh Y, Batah H, Rauf A, Nakitandwe J, Bosler DS, Jain AG, Molina JC, Balderman S, Singh A, Gerds AT, Mukherjee S, Sobecks RM, Advani AS, Carraway HE, Astbury C, Mustafa Ali MKAm J HematolPMID 40642970
  7. 2025
    Comparing Outcomes of First-Line Intensive Chemotherapeutic Regimens in Adult Patients With Acute Lymphoblastic Leukemia at a Tertiary Center
    Mohamed A, Zabor EC, Patel M, Zureigat H, Albliwi M, Chen MJ, Nakitandwe J, Bosler DS, Kurish H, Jain AG, Molina JC, Balderman S, Singh A, Gerds AT, Mukherjee S, Carraway HE, Advani AS, Mustafa Ali MKClin Lymphoma Myeloma LeukPMID 40500615
  8. 2025
  9. 2025
    Impact of TP53 mutation on survival outcomes in acute lymphoblastic leukemia at a tertiary center
    Patel M, Zabor EC, Mohamed A, Zureigat H, Chen MJ, Nakitandwe J, Tu ZJ, Jain AG, Molina JC, Balderman S, Singh A, Gerds AT, Mukherjee S, Carraway HE, Advani AS, Mustafa Ali MKLeuk LymphomaPMID 40202018
  10. 2025
    Navigating the 2022 International Consensus and World Health Organization Classifications of Hematopathology: A Call for Unified Diagnostic Language
    Zureigat H, Adcock B, Nurse DP, Rauf A, Batah H, Ondeck M, Honnekeri B, Mercer M, Jia X, Rump M, Mirza KM, Al Hadidi S, Mustafa Ali MKArch Pathol Lab MedPMID 38952288
  11. 2024
    Large Granular Lymphocytic Leukemia: Clinical Features, Molecular Pathogenesis, Diagnosis and Treatment
    Ullah F, Markouli M, Orland M, Ogbue O, Dima D, Omar N, Mustafa Ali MKCancers (Basel)PMID 38610985
  12. 2024
    Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal Degradation
    Lee JK, Chatterjee A, Scarpa M, Bailey CM, Niyongere S, Singh P, Mustafa Ali MK, Kapoor S, Wang Y, Silvestri G, Baer MRCancer Res CommunPMID 38284896
  13. 2023
    Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology
    GuidelinePollyea DA, Altman JK, Assi R, Bixby D, Fathi AT, Foran JM, Gojo I, Hall AC, Jonas BA, Kishtagari A, Lancet J, Maness L, Mangan J, Mannis G, Marcucci G, Mims A, Moriarty K, Mustafa Ali M, Neff J, Nejati R, Olin R, Percival ME, Perl A, Przespolewski A, Rao D, Ravandi F, Shallis R, Shami PJ, Stein E, Stone RM, Sweet K, Thota S, Uy G, Vachhani P, Cassara CJ, Freedman-Cass DA, Stehman KJ Natl Compr Canc NetwPMID 37156478
  14. 2023
    Impact of KRAS and NRAS mutations on outcomes in acute myeloid leukemia
    Mustafa Ali MK, Williams MT, Corley EM, AlKaabba F, Niyongere SLeuk LymphomaPMID 37042657
  15. 2023
    Institutional disparities in the distribution of the American Society of Clinical Oncology grants
    Al Hadidi S, Abu Zaid MI, Mustafa Ali MJ Cancer PolicyPMID 36649905
  16. 2023
    Outcomes of Busulfan, Fludarabine, and 400 cGy Total Body Irradiation Compared With Busulfan and Fludarabine Reduced-Intensity Conditioning Regimens for Allogeneic Stem Cell Transplantation in Adult Patients With Hematologic Diseases: A Single-Center Experience
    Alkhaldi H, Goloubeva O, Rapoport AP, Dahiya S, Pang Y, Ali MM, Hardy NM, Mohindra P, Bukhari A, Lutfi F, Sanchez-Petitto G, Molitoris J, Samanta S, Li X, Toth T, Landau M, Hodges S, Nishioka J, Ruehle K, Ridge L, Gahres N, Kocoglu MH, Atanackovic D, Malinou JN, Yared JATransplant ProcPMID 36635141
  17. 2022
    Musculoskeletal System and Connective Tissue Related Hospital Admission in England and Wales Between 1999 and 2019: An Ecologic Study
    Mustafa Ali S, Naser AY, Alghanemi AG, AbuAlhommos AK, Sabha M, Mustafa Ali MK, Hemmo SI, Alrajeh AM, Alqahtani JS, Aldhahir AM, Abu Rokbah HCureusPMID 36644035
  18. 2022
    Hospital Admissions Secondary to Diseases of the Blood, Blood-Forming Organs, and Immune System in England and Wales
    Mustafa Ali MK, Naser AY, AbuAlhommos A, Al-Daghastani T, Alrawashdeh H, Mustafa Ali S, Alwafi H, Alqurashi MM, Basha Ahmed AH, Albarqi HCureusPMID 36397897
  19. 2022
    A Focus on Intermediate-Risk Acute Myeloid Leukemia: Sub-Classification Updates and Therapeutic Challenges
    Awada H, Mustafa Ali MK, Thapa B, Awada H, Seymour L, Liu L, Gurnari C, Kishtagari A, Wang E, Baer MRCancers (Basel)PMID 36077703
  20. 2022
    Trends in Hospital Admissions Due to Neoplasms in England and Wales between 1999 and 2019: An Ecological Study
    Naser AY, Alwafi H, Hemmo SI, Alrawashdeh HM, Alqahtani JS, Alghamdi SM, Mustafa Ali MKInt J Environ Res Public HealthPMID 35805710
  21. 2022
    Patterns of treatment and their outcomes in primary breast lymphoma; a comprehensive population-based analysis
    Mustafa Ali MK, Samhouri Y, Law JY, Khan C, Wegner R, Lee ST, Lister JBreast CancerPMID 35788963
  22. 2022
    Impact of FLT3-ITD Insertion Length on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study
    Corley EM, Mustafa Ali MK, Alharthy H, Kline KAF, Sewell D, Law JY, Lee ST, Niyongere S, Duong VH, Baer MR, Emadi ABiology (Basel)PMID 35741439
  23. 2022
    Consolidative Autologous Stem Cell Transplantation Versus Whole Brain Radiation in PCNSL; a Nationwide Analysis
    Samhouri Y, Mustafa Ali MK, Law J, Khan C, Wegner R, Lee ST, Lister JClin Lymphoma Myeloma LeukPMID 35705438
  24. 2022
    Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study
    Mustafa Ali MK, Corley EM, Alharthy H, Kline KAF, Law JY, Lee ST, Niyongere S, Duong VH, Emadi A, Baer MRFront OncolPMID 35433414
  25. 2022
    Impact of IDH1 c.315C>T SNP on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study
    Corley EM, Mustafa Ali MK, Alharthy H, Kline KAF, Sewell D, Law JY, Lee ST, Niyongere S, Duong VH, Baer MR, Emadi AFront OncolPMID 35372066
  26. 2022
  27. 2022
    Low utility of the H-Score and HLH-2004 criteria to identify patients with secondary hemophagocytic lymphohistiocytosis after CAR-T cell therapy for relapsed/refractory diffuse large B-Cell lymphoma
    Kim DW, Bukhari A, Lutfi F, Zafforoni F, Merechi F, Mustafa Ali MK, Gottlieb D, Lee ST, Kocoglu MH, Hardy NM, Yared J, Rapoport AP, Dahiya S, Law JYLeuk LymphomaPMID 35045791
  28. 2021
    Hospital admission trends due to respiratory diseases in England and Wales between 1999 and 2019: an ecologic study
    Naser AY, Mansour MM, Alanazi AFR, Sabha O, Alwafi H, Jalal Z, Paudyal V, Dairi MS, Salawati EM, Alqahtan JS, Alaamri S, Mustafa Ali MKBMC Pulm MedPMID 34749696
  29. 2021
    The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma
    Lutfi F, Holtzman NG, Kansagra AJ, Mustafa Ali M, Bukhari A, Yan J, Samanta S, Gottlieb D, Kim DW, Matsumoto LR, Gahres N, Ruehle K, Lee ST, Law JY, Kocoglu MH, Atanackovic D, Yared JA, Hardy NM, Molitoris J, Mohindra P, Rapoport AP, Dahiya SBr J HaematolPMID 34500492
  30. 2021
    Hospital Admissions Due to Ischemic Heart Diseases and Prescriptions of Cardiovascular Diseases Medications in England and Wales in the Past Two Decades
    Hemmo SI, Naser AY, Alwafi H, Mansour MM, Alanazi AFR, Jalal Z, Alsairafi ZK, Paudyal V, Alomari E, Al-Momani H, Salawati EM, Samannodi M, Dairi MS, Al Bawab AQ, Mustafa Ali MK, Alkharabsheh SInt J Environ Res Public HealthPMID 34280978
  31. 2021
    Increased body mass index is a risk factor for acute promyelocytic leukemia
    Kashanian SM, Li AY, Mustafa Ali M, Sutherland ME, Duong VH, Hambley BC, Zacholski K, El Chaer F, Holtzman NG, Imran M, Patzke CL, Cornu J, Duffy A, Dezern AE, Gojo I, Norsworthy KJ, Levis MJ, Smith BD, Baer MR, Ghiaur G, Emadi AEJHaemPMID 33693438
  32. 2021
    Hospitalization and Post-hospitalization Outcomes Among Teaching Internal Medicine, Employed Hospitalist, and Locum Tenens Hospitalist Services in a Tertiary Center: a Prospective Cohort Study
    Mustafa Ali MK, Sabha MM, Mustafa SK, Banifadel M, Ghazaleh S, Aburayyan KM, Ghanim MT, Awad MT, Gekonde DN, Ambati AR, Ramahi A, Elzanaty AM, Nesheiwat Z, Shastri PM, Al-Sarie M, McGready JJ Gen Intern MedPMID 33495887
  33. 2021
    Chimeric antigen receptor T-cell therapy after allogeneic stem cell transplant for relapsed/refractory large B-cell lymphoma
    Lutfi F, Holtzman N, Siglin J, Bukhari A, Mustafa Ali M, Kim D, Sanchez-Petitto G, Gottlieb D, Ruehle K, Hutnick E, Gahres N, Hankey K, Lee S, Kocoglu M, Yared J, Hardy N, Rapoport A, Dahiya SBr J HaematolPMID 33169845
  34. 2018
    Intravenous compared to oral busulfan with cyclophosphamide for autologous hematopoietic cell transplant conditioning for plasma cell myeloma
    Mustafa Ali M, Corrigan DM, Rybicki LA, Yurch MA, Cherni K, Liu H, Dean R, Hamilton B, Pohlman B, Andresen S, Kalaycio M, Bolwell BJ, Majhail NS, Sobecks RHematol Oncol Stem Cell TherPMID 29705567
  35. 2017
    Long-term peripheral neuropathy symptoms in breast cancer survivors
    Mustafa Ali M, Moeller M, Rybicki L, Moore HCFBreast Cancer Res TreatPMID 28791499
  36. 2017
    Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era
    Mustafa Ali M, Rybicki L, Nomani L, Rouphail B, Dean RM, Hill BT, Jagadeesh D, Pohlman B, Hsi ED, Smith MRClin Lymphoma Myeloma LeukPMID 28789937
  37. 2017
  38. 2017
    Hemophagocytic Lymphohistiocytosis in a Patient With Hodgkin lymphoma and Concurrent EBV, CMV, and Candida Infections
    Mustafa Ali M, Ruano Mendez AL, Carraway HEJ Investig Med High Impact Case RepPMID 28210636
  39. 2017
    Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic Syndrome
    Mustafa Ali M, Abounader DM, Rybicki LA, Yurch MA, Starn J, Ferraro C, Winslow V, Hamilton BK, Gerds AT, Liu H, Dean R, Hill BT, Pohlman B, Andresen S, Hanna R, Kalaycio M, Bolwell BJ, Majhail NS, Sobecks RMBiol Blood Marrow TransplantPMID 28108271
  40. 2015
  41. 2014
    The prevalence of isolated growth hormone deficiency among children of short stature in Jordan and its relationship with consanguinity
    Zayed AA, Mustafa Ali MK, Al-Ani MA, Momani MS, Yousef AMClin Endocrinol (Oxf)PMID 25041402
Portrait of Dr. Saja Mustafa Ali, MD
Rheumatology

Dr. Saja Mustafa Ali, MD

Medical Advisor at AEcelerate

A board-certified rheumatologist at the University of Chicago Medicine, Saja co-authored systematic meta-analyses in autoimmunity and population-health studies of hospital admissions in England and Wales.

3PubMed-indexed publications
2022 – 2023Publication years
PubMed author record
  1. 2023
  2. 2022
    Musculoskeletal System and Connective Tissue Related Hospital Admission in England and Wales Between 1999 and 2019: An Ecologic Study
    Mustafa Ali S, Naser AY, Alghanemi AG, AbuAlhommos AK, Sabha M, Mustafa Ali MK, Hemmo SI, Alrajeh AM, Alqahtani JS, Aldhahir AM, Abu Rokbah HCureus
  3. 2022
    Hospital Admissions Secondary to Diseases of the Blood, Blood-Forming Organs, and Immune System in England and Wales
    Mustafa Ali MK, Naser AY, AbuAlhommos A, Al-Daghastani T, Alrawashdeh H, Mustafa Ali S, Alwafi H, Alqurashi MM, Basha Ahmed AH, Albarqi HCureus
Portrait of Caroline McGuirk, MBA
Healthcare Strategy & AI Commercialization

Caroline McGuirk, MBA

COO at AEcelerate

A healthcare strategy and technology professional, Caroline leads operations and commercialization at AEcelerate and holds the U.S. patent-pending application on the platform’s integrated multi-platform AI architecture for automated adverse-event detection and regulatory reporting. Her background spans healthcare SaaS, market strategy, regulatory analysis, and technology commercialization; she holds an MBA from Johns Hopkins University in Health Care Management, Innovation & Technology, with Stanford certifications in Generative AI and AI in Healthcare.

1U.S. patent pending (architecture)
2026Publication years
LinkedIn profile
  1. 2026
The evidence layer

Peer-reviewed rigor, built into the product.

The same standards our leadership brings to clinical research and publication carry into every workflow AEcelerate ships.